Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Casey Paleos

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Affective Disorders|July 9, 2022
At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trialThomas D Hull, Matteo Malgaroli, Adam Gazzaley, et al.
Nature Medicine|September 14, 2023
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trialJennifer M Mitchell, Marcela Ot'alora G, Bessel van der Kolk, et al.
Focus (American Psychiatric Publishing)|July 5, 2023
MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 StudyJennifer M Mitchell, Michael Bogenschutz, Alia Lilienstein, et al.
Nature Medicine|May 11, 2021
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 studyJennifer M Mitchell, Michael Bogenschutz, Alia Lilienstein, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Affective Disorders|July 9, 2022
At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trialThomas D Hull, Matteo Malgaroli, Adam Gazzaley, et al.
Nature Medicine|September 14, 2023
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trialJennifer M Mitchell, Marcela Ot'alora G, Bessel van der Kolk, et al.
Focus (American Psychiatric Publishing)|July 5, 2023
MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 StudyJennifer M Mitchell, Michael Bogenschutz, Alia Lilienstein, et al.
Nature Medicine|May 11, 2021
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 studyJennifer M Mitchell, Michael Bogenschutz, Alia Lilienstein, et al.
Pageof 1